文献速递复苏、休克与脓毒症重症综合管理与镇静镇痛

ICU前平衡晶体液与生理盐水对脓毒症死亡率的影响:倾向性评分匹配的多中心队列研究

Impact of Pre-ICU Balanced Crystalloids vs Saline on Mortality in Sepsis: A Propensity Score-Matched Multicenter Cohort Study.
PubMed 文献 · Chest · 2026-09-19
一句话结论脓毒症患者ICU前使用平衡晶体液较生理盐水与30天死亡率降低相关(校正OR 0.69,95%CI 0.56-0.83)。

倾向性评分匹配后每组1335例,平衡晶体液组30天死亡率显著更低(校正OR 0.69,95%CI 0.56-0.83),IPTW分析结果一致(校正OR 0.78,95%CI 0.69-0.88)。平衡晶体液还与ICU期间持续肾脏替代治疗需求减少、ICU出院时肾脏替代治疗减少及28天无呼吸机天数增加相关。

要点

  • 脓毒症患者ICU前使用平衡晶体液与30天死亡率降低独立相关:倾向性评分匹配后校正OR 0.69(95%CI 0.56-0.83)。
  • 逆概率治疗加权(IPTW)分析验证结果稳健:校正OR 0.78(95%CI 0.69-0.88)。
  • 亚组一致:年龄、性别、疾病严重度、ICU前液体量>30 mL/kg、ICU前使用血管活性药均未见效应异质性。
  • 平衡晶体液组ICU期间持续肾脏替代治疗需求减少、ICU出院时肾脏替代治疗减少、28天无呼吸机天数增加。
  • mortality风险降低在无慢性肾脏病、于急诊或病房接受液体、基线氯≤110 mmol/L及基线pH<7.35的患者中更显著。

适用人群与场景

  • 成人脓毒症患者,于ICU入住前接受初始液体复苏;研究排除标准原文未提及。
  • 场景为ICU前阶段(急诊、病房、手术室或其他ICU)。

诊断标准与关键阈值

  • 脓毒症诊断标准原文未提及;分组依据为ICU前初始复苏使用平衡晶体液或0.9%生理盐水。
  • 亚组阈值:ICU前液体量>30 mL/kg、基线氯≤110 mmol/L、基线pH<7.35。

处置流程与药物剂量

  • 原文未给出具体液体剂量、输注速度或目标值,仅比较ICU前初始复苏阶段使用平衡晶体液 vs 0.9%生理盐水。
  • 原文未提及具体药物剂量、给药途径、频次或疗程。

红旗征与不能漏的情况

  • 原文未提及

研究设计与关键结果

  • 研究类型:全国多中心回顾性队列研究;样本量3688例(平衡晶体液1381例,生理盐水2307例);倾向性评分匹配后每组1335例。
  • 主要终点:30天死亡率,平衡晶体液组校正OR 0.69(95%CI 0.56-0.83);IPTW分析校正OR 0.78(95%CI 0.69-0.88)。
  • 关键次要终点:平衡晶体液组ICU期间持续肾脏替代治疗需求减少、ICU出院时肾脏替代治疗减少、28天无呼吸机天数增加。
  • 亚组分析:年龄、性别、疾病严重度、ICU前液体量>30 mL/kg、ICU前血管活性药使用均未见效应异质性;无慢性肾脏病、急诊或病房接受液体、基线氯≤110 mmol/L、基线pH<7.35者死亡风险降低更显著。

证据类型、等级与局限

  • 证据类型:多中心回顾性队列研究(非随机);原文未给出证据等级或推荐强度。
  • 局限:回顾性设计、可能存在未测量混杂(尽管采用倾向性评分匹配和IPTW)、原文未提及单中心或开放标签等细节。

对床旁实践的改变

  • 对脓毒症患者,ICU前初始复苏可考虑优先使用平衡晶体液而非0.9%生理盐水,以降低30天死亡率(基于本回顾性队列的关联,非因果结论)。
  • 在无慢性肾脏病、于急诊或病房开始复苏、基线氯≤110 mmol/L或基线pH<7.35的患者中,平衡晶体液的获益信号更明显。
  • 原文未提供具体液体量、速度或监测目标,不能据此制定剂量方案;需结合临床个体化决策。

指南或共识出处

  • 原文未提及指南或共识名称;研究发表于Chest。

以上提炼依据论文摘要(全文未开放获取,或许可不允许翻译转载);全文请点「阅读原文」。

英文原文(摘要)· 点击展开

BACKGROUND: The optimal crystalloids for initial fluid resuscitation in sepsis remain uncertain. Most previous studies have focused on the ICU, leaving the pre-ICU admission impact of crystalloid type unclear.

RESEARCH QUESTION: Is there an association between pre-ICU admission crystalloid type administration and clinical outcomes in patients with sepsis?

STUDY DESIGN AND METHODS: This nationwide multicenter retrospective cohort study analyzed adult patients with sepsis between September 2019 and December 2023. Patients receiving initial fluid resuscitation before ICU admission were categorized into balanced crystalloid or 0.9% sodium chloride (saline) groups. The primary outcome was 30-day mortality.

RESULTS: Among 3,688 patients (mean age ± SD, 71.9 ± 13.8 years; 58% male), 1,381 (37.4%) received balanced crystalloids, and 2,307 (62.6%) received saline before ICU admission. After propensity score matching, 1,335 patients remained in each group. Balanced crystalloid use was associated with lower 30-day mortality, resulting in an adjusted OR of 0.69 (95% CI, 0.56-0.83). The finding was consistent after inverse probability of treatment weighting (adjusted OR, 0.78; 95% CI, 0.69-0.88). The association between balanced crystalloids and mortality was consistent across age, sex, disease severity, liberal fluid management (pre-ICU fluid volume > 30 mL/kg), and pre-ICU vasopressor use. Notably, the mortality risk was lower with balanced crystalloids in patients without chronic kidney disease, who received fluids in the emergency department or ward (vs operating room or other ICU), with a baseline chloride ≤ 110 mmol/L, and with a baseline pH < 7.35. Furthermore, balanced crystalloid use was associated with reduced need for continuous renal replacement therapy during ICU stay, reduced renal replacement therapy at ICU discharge, and increased 28-day ventilator-free days.

INTERPRETATION: Our results show that when compared with saline, pre-ICU administered balanced crystalloid use was associated with lower 30-day mortality in patients with sepsis.

来源:Chest,查看原文。版权归原作者所有。

参考来源

  1. Kim TW, Kim Y, Baek MS, et al. Impact of Pre-ICU Balanced Crystalloids vs Saline on Mortality in Sepsis: A Propensity Score-Matched Multicenter Cohort Study. Chest. 2026. PMID: 42762986. doi:10.1016/j.chest.2026.09.008

供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。